A recent study showed that cancer cells can be sensitized for effective immunotherapy by sgRNA CRISPR-Cas9-mediated knockout of PTPN2, resulting in the upregulation of HLA class I surface molecules, similarly to what we observed for beta cells [41]. Here, PTPN2 is linked to cancer.